Testosterone replacement therapy (TRT) for hypogonadism has faced significant scrutiny regarding its cardiovascular safety. Historical data demonstrate that low testosterone levels are associated with adverse metabolic profiles and increased cardiovascular risk, as evidenced by multiple large-scale epidemiological studies. While early studies raised concerns about cardiovascular risks with TRT, these investigations had significant methodological limitations. Three recent landmark trials—TRAVERSE (n = 5246), T4DM (n = 1003), and the Testosterone Trials (n = 790)—have provided definitive evidence regarding testosterone cardiovascular safety. The FDA-mandated TRAVERSE trial demonstrated no increase in major adverse cardiovascular events (MACE) with TRT compared to placebo (7.0% vs 7.3%) in high-risk men. The T4DM trial showed cardiometabolic benefits, while the Testosterone Trials provided comprehensive safety data across multiple health domains. Contemporary evidence supports the cardiovascular safety of TRT, with some data suggesting metabolic benefits in specific populations. These findings enable clinicians to confidently prescribe testosterone therapy to hypogonadal men while maintaining appropriate patient selection and monitoring protocols.